Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fluparoxan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 5/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.37 |
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.37 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.37 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.33 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.33 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.33 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.33 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.33 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluparoxan SCHEMBL9482018 | 1.00 | HTR6 (0.38) | HTR6CA2SLC6A2SLC6A4CHRNB2 | |
| Fluparoxan SCHEMBL9482026 | 1.00 | HTR6 (0.38) | HTR6CA2SLC6A2SLC6A4CHRNB2 | |
| Fluparoxan SCHEMBL112164 | 0.98 | SLC6A2 (0.38) | HTR6CA2SLC6A2SLC6A4CHRNB2 | |
| Fluparoxan SCHEMBL29401005 | 0.98 | SLC6A2 (0.38) | HTR6CA2SLC6A2SLC6A4CHRNB2 | |
| Fluparoxan SCHEMBL7173629 | 0.98 | SLC6A2 (0.38) | HTR6CA2SLC6A2SLC6A4CHRNB2 | |
| Fluparoxan SCHEMBL9570339 | 0.98 | SLC6A2 (0.38) | HTR6CA2SLC6A2SLC6A4CHRNB2 | |
| Hydrochloric Acid SCHEMBL10579193 | 0.83 | BRD4 (0.36) | HTR6SLC6A2SLC6A4SLC6A3HTR2C | |
| Hydrochloric Acid SCHEMBL10377423 | 0.81 | CHRNB2 (0.33) | SLC6A2SLC6A4CHRNB2CHRNA4SLC6A3 | |
| Hydrochloric Acid SCHEMBL10377421 | 0.81 | CHRNB2 (0.33) | SLC6A2SLC6A4CHRNB2CHRNA4SLC6A3 | |
| SCHEMBL10375117 | 0.81 | BRD4 (0.36) | HTR6SLC6A2SLC6A4CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5190967-A | Sexual dysfunction | GLAXO GROUP LIMITED (GB) | 1993-03-02 | — | — | US | claimed |
| EP-0460912-A2 | Medicaments for the treatment of sexual disorder | GLAXO GROUP LIMITED (GB) | 1991-12-11 | — | — | EP | claimed |
| US-5032603-A | Tranquilizers | GLAXO GROUP LIMITED (GB) | 1991-07-16 | — | — | US | claimed |
| US-5010096-A | Administering benzodioxino pyrrole compounds; adrenergic blocking agents | GLAXO GROUP LIMITED (GB) | 1991-04-23 | — | — | US | claimed |
| EP-0407016-A2 | Use of benzodioxinopyrrole derivatives in the manufacture of a medicament for the treatment of anxiety | GLAXO GROUP LIMITED (GB) | 1991-01-09 | — | — | EP | claimed |
| EP-0162593-B1 | HETEROCYCLIC AMINO COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1990-08-16 | — | — | EP | claimed |
| EP-0371793-A2 | Use of a benzodioxinopyrrole derivatives for the preparation of a medicament in the treatment of cerebral ischaemia | GLAXO GROUP LIMITED (GB) | 1990-06-06 | — | — | EP | claimed |
| US-4880801-A | ALPHA 2-ADRENORECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 1989-11-14 | — | — | US | claimed |
| EP-0162593-A1 | Heterocyclic amino compounds | GLAXO GROUP LIMITED (GB) | 1985-11-27 | — | — | EP | claimed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| EP-0162593-B1 | HETEROCYCLIC AMINO COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1990-08-16 | — | — | EP | disclosed |
| EP-0221725-B1 | PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1990-08-08 | — | — | EP | disclosed |
| US-4880801-A | ALPHA 2-ADRENORECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 1989-11-14 | — | — | US | disclosed |
| US-4837336-A | Process for preparing heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 1989-06-06 | — | — | US | disclosed |
| EP-0221725-A2 | Process for preparing heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 1987-05-13 | — | — | EP | disclosed |
| EP-0162593-A1 | Heterocyclic amino compounds | GLAXO GROUP LIMITED (GB) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | HTR6 55/4885CA2 4662/4885SLC6A2 3/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | HTR6 55/4885CA2 4662/4885SLC6A2 3/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | HTR6 55/4885CA2 4662/4885SLC6A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.